ScholarLens Back to search
2011•Unpublished venueRequires access

SABCS: Updated BOLERO-2 Findings Confirm Efficacy of Everolimus Plus Exemestane

Michael Kaufman

Open publisher page 0 citations

Abstract

Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in progression-free survival (PFS) in women with metastatic breast cancer when the immunosuppressant agent is combined with the hormonal therapy exemestane.

About this research paper

What this paper is about

Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in progression-free survival (PFS) in women with metastatic breast cancer when the immunosuppressant agent is combined with the hormonal therapy exemestane.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in progression-free survival (PFS) in women with metastatic breast cancer when the immunosuppressant agent is combined with the hormonal therapy exemestane.

Key concepts: Exemestane, Everolimus, Medicine, Oncology, Internal medicine, Breast cancer, Metastatic breast cancer, Aromatase

Back to paper searchBrowse research topicsOriginal source
SABCS: Updated BOLERO-2 Findings Confirm Efficacy of Everolimus Plus Exemestane — Research Paper | ScholarLens